Table 4.
Correlations between FUCA2 expression and clinicopathological parameters of PCa patients.
| Characteristic | Low expression of FUCA2 n (%) | High expression of FUCA2 n (%) | p-Value |
|---|---|---|---|
| Patients | 249 (40.9%) | 250 (50.1%) | |
| Age | 0.896*** | ||
| ≤60 | 113 (22.6%) | 111 (22.2%) | |
| >60 | 136 (27.3%) | 139 (27.9%) | |
| PSA (ng/ml) | 0.112* | ||
| <4 | 203 (45.9%) | 212 (48%) | |
| ≥4 | 18 (4.1%) | 9 (2%) | |
| Pathological grade group | 0.001* | ||
| Low-grade group (Gleason score < 8) |
126 (25.28%) | 167 (33.5%) | |
| High-grade group (Gleason score ≥ 8) |
123 (24.6%) | 83 (16.6%) | |
| T stage | 0.005* | ||
| T2 | 79 (16.1%) | 110 (22.4%) | |
| T3 and T4 | 166 (33.7%) | 137 (27.8%) | |
| N stage | 0.007* | ||
| N0 | 167 (39.2%) | 180 (42.3%) | |
| N1 | 52 (12.2%) | 27 (6.3%) | |
| M stage | 0.618** | ||
| M0 | 232 (50.7%) | 223 (48.7%) | |
| M1 | 1 (0.2%) | 2 (0.4%) | |
| Primary therapy outcome | 0.008* | ||
| PR and CR | 182 (41.6%) | 199 (45.5%) | |
| PD and SD | 38 (8.6%) | 19 (4.4%) | |
| Residual tumor | 0.023* | ||
| R0 | 145 (31%) | 170 (36.3%) | |
| R1 and R2 | 88 (18.8%) | 65 (13.9%) | |
| OS event | 0.751** | ||
| Alive | 245 (49.1%) | 244 (48.9%) | |
| Dead | 4 (0.8%) | 6 (1.2%) | |
| DSS event | 0.373** | ||
| Alive | 246 (49.5%) | 246 (49.5%) | |
| Dead | 1 (0.2%) | 4 (0.8%) | |
| PFI event | 0.049* | ||
| Alive | 193 (38.7%) | 212 (42.5%) | |
| Dead | 56 (11.2%) | 38 (7.6%) |
p < 0.05 is considered as statistically significant.
PCa, prostate cancer; BPH, benign prostate hyperplasia; OS, overall survival; DSS, disease-specific survival; PFI, progression-free interval; PSA, prostate-specific antigen; PR, partial response; CR, complete response; PD, progressive disease; SD, stable disease.
*p: chi-square test.
**p: Fisher’s test.
***p: Wilcoxon rank-sum test.